ENZ Stock Overview
Develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Enzo Biochem, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$1.15 |
52 Week High | US$1.50 |
52 Week Low | US$0.99 |
Beta | 0.73 |
11 Month Change | 2.68% |
3 Month Change | 2.68% |
1 Year Change | -14.18% |
33 Year Change | -66.18% |
5 Year Change | -63.49% |
Change since IPO | -93.79% |
Recent News & Updates
Recent updates
Enzo Biochem: Is This Time Finally Different?
Jul 17Enzo Biochem: Cleaned Up And Cash-Rich But Unloved
Oct 26Is Enzo Biochem (NYSE:ENZ) Using Debt Sensibly?
May 18Is Enzo Biochem (NYSE:ENZ) A Risky Investment?
Jan 03Enzo Biochem Non-GAAP EPS of -$0.18, revenue of $18.28M
Dec 12Enzo Biochem appoints Patricia Eckert as interim CFO
Oct 20Enzo Biochem Non-GAAP EPS of -$0.17, revenue of $20.28M
Oct 14Does Enzo Biochem (NYSE:ENZ) Have A Healthy Balance Sheet?
Oct 04Enzo Biochem: Activist Pressure Could Finally Lead To A Company Sale
Jun 27Is Enzo Biochem (NYSE:ENZ) Using Debt In A Risky Way?
May 03Is Enzo Biochem (NYSE:ENZ) A Risky Investment?
Dec 17Health Check: How Prudently Does Enzo Biochem (NYSE:ENZ) Use Debt?
Aug 24Does Enzo Biochem (NYSE:ENZ) Have A Healthy Balance Sheet?
Mar 01Is Enzo Biochem, Inc. (NYSE:ENZ) Popular Amongst Insiders?
Feb 03If You Had Bought Enzo Biochem's (NYSE:ENZ) Shares Three Years Ago You Would Be Down 66%
Jan 08Enzo Biochem nabs expanded EUA nod for testing of COVID samples
Jan 04Enzo Biochem: Betting On The Activists Now
Dec 16Here's What We Think About Enzo Biochem's (NYSE:ENZ) CEO Pay
Dec 13Shareholder Returns
ENZ | US Healthcare | US Market | |
---|---|---|---|
7D | 0.9% | -0.5% | 0.5% |
1Y | -14.2% | 2.3% | 36.8% |
Return vs Industry: ENZ underperformed the US Healthcare industry which returned 1.1% over the past year.
Return vs Market: ENZ underperformed the US Market which returned 38.6% over the past year.
Price Volatility
ENZ volatility | |
---|---|
ENZ Average Weekly Movement | 3.5% |
Healthcare Industry Average Movement | 6.7% |
Market Average Movement | 6.1% |
10% most volatile stocks in US Market | 15.0% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ENZ has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ENZ's weekly volatility (3%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1976 | 185 | Kara Cannon | www.enzo.com |
Enzo Biochem, Inc. develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. It also provides AMPIVIEW in situ hybridization probes for enhanced detection of low expressed targets useful in the growing spatial biology space; reagents and assays for cell and gene therapy research and development; POLYVIEW PLUS Enhanced Immunohistochemistry platform, offers solutions within the area of anatomical pathology through optimized assays; Enhanced Immunoassays, pushing sensitivity to expand immunoassay applications for basic research, bioprocess, and diagnostics; AMPIPROBE, a nucleic acid amplification platform; and Axxora.com, a proven distribution platform for original manufacturers of innovative research reagents.
Enzo Biochem, Inc. Fundamentals Summary
ENZ fundamental statistics | |
---|---|
Market cap | US$58.15m |
Earnings (TTM) | -US$9.82m |
Revenue (TTM) | US$31.91m |
1.9x
P/S Ratio-6.0x
P/E RatioIs ENZ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ENZ income statement (TTM) | |
---|---|
Revenue | US$31.91m |
Cost of Revenue | US$17.28m |
Gross Profit | US$14.63m |
Other Expenses | US$24.45m |
Earnings | -US$9.82m |
Last Reported Earnings
Jul 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.19 |
Gross Margin | 45.86% |
Net Profit Margin | -30.77% |
Debt/Equity Ratio | 0.3% |
How did ENZ perform over the long term?
See historical performance and comparison